Predicting Left Ventricular Dilation following Myocardial Infarction by Protease and Protease Inhibitor Profiling


Technology: This invention relates to a method of predicting diastolic heart failure in a patient, by identifying, from their body fluid, a profile of MMPs and TIMPs that is associated with the development of left ventricular dilation (LVD). This biomarker panel can identify these patients shortly (1-5 days) after their infarct occurs.




Worldwide, more than seven million people die due to coronary heart disease; 450,000 in the US alone. Myocardial infarction (MI) is one of the five main manifestations of coronary heart disease. Following presentation of myocardial infarction, a left ventricular (LV) remodeling process occurs in patients. The rate and extent of this post-MI remodeling process has been established to be independent predictors of morbidity and mortality. Identification of those patients at greatest risk for developing post-MI remodeling holds great diagnostic/therapeutic relevance. Current biomarkers used to identify MI are Troponin and CK-MB. However, these are acute markers of infarct and do not offer insight into which patients are at greatest risk for remodeling. Matrix metalloproteinases (MMPs) and tissue inhibitor matrix metalloproteinases (TIMPS), which have only recently been discovered in the heart, will lead the charge in predicting patients at risk for LV remodeling and encourage preventative care.



Earlier identification of patients at risk for LV remodeling post-MI presentation


Key Words: Hypertrophic heart failure, congestive heart failure - CHF, heart failure with reduced ejection fraction – HFrEF, myocardial infarction, LV remodeling, hypertension, obesity, diabetes, diagnostic


Publications: Zavadzkas, Juozas A., et al. "Direct regulation of membrane type 1 matrix

metalloproteinase following myocardial infarction causes changes in survival, cardiac function,

and remodeling." American Journal of Physiology-Heart and Circulatory Physiology 301.4

(2011): H1656-H1666.


Spinale, Francis G., et al. "Cardiac restricted overexpression of membrane type-1 matrix

metalloproteinase causes adverse myocardial remodeling following myocardial

infarction." Journal of Biological Chemistry 285.39 (2010): 30316-30327.


Inventors:  F.G. Spinale, M.R. Zile, R.E. Stroud                

Patent Status: US Patent 8,445,222

MUSC-FRD Technology ID: P0617 

Patent Information:
For Information, Contact:
Scott Davis
Associate Director, Licensing
MUSC Foundation for Research Development
Francis Spinale
Robert Stroud
Michael Zile
© 2022. All Rights Reserved. Powered by Inteum